ArticleAntimicrobial agents and chemotherapy2024
Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in
Abstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global trends and research profile of antibiotic heteroresistance: a bibliometric and visual analysis.Frontiers in microbiology · 2026Pooled it
- Beyond Carbapenemases: Chromosomal Resistance Mechanisms and Carbapenemase Type Determine Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Mechanisms involved in cefiderocol resistance in FrenchAntimicrobial agents and chemotherapy · 2026Article
- Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions.Antibiotics (Basel, Switzerland) · 2026Review
- Loss of the ferripyochelin receptor FptA drives reduced cefiderocol susceptibility and impairs fitness inAntimicrobial agents and chemotherapy · 2026Article
- Genetic basis of cefiderocol resistance inMicrobiology spectrum · 2026Article
- Magnesium depletion by Candida albicans unleashes two unusual modes of colistin resistance in Pseudomonas aeruginosa with different fitness costs.PLoS biology · 2026Article
- Genomic diversity and adaptive resistance mechanisms inmSystems · 2026Article
- MexS mediated heteroresistance ofFrontiers in microbiology · 2026Article
- Nutrient-driven small-colony variants as an adaptive outcome in Carbapenem-resistantCurrent research in microbial sciences · 2026Article
- Newer antibiotics for drug-resistant Gram-negative infections in immunocompromised hosts: from pivotal trials to high-risk practice.Frontiers in cellular and infection microbiology · 2026Review
- Siderophore cephalosporins.EcoSal Plus · 2025Review
- Current and future options for the treatment of serious infections due to carbapenem-resistantClinical microbiology reviews · 2025Review
- Loss of the Ferripyochelin Receptor FptA Drives Reduced Cefiderocol Susceptibility and Impairs Fitness inbioRxiv : the preprint server for biology · 2025Article
- Cefepime-zidebactam therapy for extensively drug-resistantJAC-antimicrobial resistance · 2025Article
- Analysis of the Alkaline Resistance Mechanism of Halomonas alkalicola CICC 11012 s by Proteomics and Metabolomics.Current microbiology · 2025Article
- Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens.Frontiers in microbiology · 2025Review
- The Role of Bacterial Siderophores in Infection Therapy: From Anti-Infective Mechanisms to Therapeutic Advances.International journal of nanomedicine · 2025Review
- Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistantJAC-antimicrobial resistance · 2024Article
- Distinct chromosomal mutation associated with cefiderocol resistance inFrontiers in microbiology · 2024Article
Corrections and comments
- Update of
Authors and funding
14 authors.
Stephanie L EggeDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0001-8232-0443
Samie A RizviDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Shelby R SimarUTHealth Houston School of Public Health, University of Texas Health Science Center, Houston, Texas, USA.
Manuel AlcaldeInstituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina Clinica Alemana, Universidad del Desarrollo and Multidisciplinary Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Chile.
Jose R W MartinezInstituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina Clinica Alemana, Universidad del Desarrollo and Multidisciplinary Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Chile.
Blake M HansonUTHealth Houston School of Public Health, University of Texas Health Science Center, Houston, Texas, USA.ORCID 0000-0003-2949-7818
An Q DinhDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Rodrigo P BaptistaDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Truc T TranDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0002-2696-4196
Samuel A ShelburneDepartment of Infectious Diseases, Infection Control, and Employee Health, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-9721-263X
Jose M MunitaInstituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina Clinica Alemana, Universidad del Desarrollo and Multidisciplinary Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Chile.
Cesar A AriasDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0001-9054-9774
Morgan HakkiDepartment of Medicine, Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA.
William R MillerDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0002-1518-2973
Funding
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SAVIDGE, TOR C. · 2020 to 2025
$12.0MVENOUS: A translational study of enterococcal bacteremiaR01AI148342 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2024
$3.9MThe LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7MMolecular Basis of Infectious Diseases Training GrantT32AI055449 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LORENZ, MICHAEL C · 2005 to 2025
$2.6MPOR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5MTexas Medical Center Training Program in Antimicrobial ResistanceT32AI141349 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GARSIN, DANIELLE A · 2019 to 2023
$1.3MEmergence of TonB-dependent receptor mediated cefiderocol resistance among multidrug-resistant (MDR) Pseudomonas aeruginosa clinical isolates.R21AI175821 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI MILLER, WILLIAM R · 2023 to 2024
$467kHHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI121296HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI134637HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI141349HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI148342HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI152999HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI175821NIAID NIH HHS K24 AI121296NIAID NIH HHS P01 AI152999NIAID NIH HHS R01 AI134637NIAID NIH HHS R01 AI148342NIAID NIH HHS R21 AI175821NIAID NIH HHS T32 AI055449NIAID NIH HHS T32 AI141349
Abstract
The siderophore-cephalosporin cefiderocol (FDC) presents a promising treatment option for carbapenem-resistant (CR)
Indexed as
Anti-Bacterial AgentsBacterial ProteinsCefiderocolMicrobial Sensitivity TestsMutationPseudomonas aeruginosaCephalosporinsDrug Resistance, BacterialHumansMembrane ProteinsPseudomonas InfectionsAnti-Bacterial AgentsBacterial ProteinsCefiderocolCephalosporinsMembrane ProteinstonB protein, Bacteriabeta-lactamasescefiderocolGram-negative resistanceheteroresistancemulti-drug resistancePseudomonas aeurginosaTonB-dependent receptor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.